clonidine has been researched along with Bilateral Headache in 36 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of tizanidine in chronic tension-type headache was compared with placebo in a randomized, double-blind and cross-over study in 37 women aged 20 to 59 years with a history of headache for 7 months to 30 years (median 5 years)." | 9.07 | Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. ( Fogelholm, R; Murros, K, 1992) |
| "Seventy-eight patients with tension-type headache (TH) were treated with tizanidine hydrochloride (tizanidine)." | 9.07 | Treatment of tension-type headache with tizanidine hydrochloride: its efficacy and relationship to the plasma MHPG concentration. ( Awaki, E; Kowa, H; Shimomura, T; Takahashi, K, 1991) |
| "We compared the effects of transdermal clonidine and oral atenolol on acute exercise performance and on conditioning response to an 8-week program of regular aerobic exercise in young, otherwise healthy subjects with mild hypertension." | 9.06 | Comparative effects of transdermal clonidine and oral atenolol on acute exercise performance and response to aerobic conditioning in subjects with hypertension. ( Davidman, M; Davies, SF; Graif, JL; Husebye, DG; Iber, C; Maddy, MM; McArthur, CD; O'Connell, MB; Path, MJ, 1989) |
| "We report a rare case of Shapiro's syndrome variantrevealed by episodes of headache with spontaneous hypothermia witheffectiveness of clonidine therapy in a 76-year-old Parkinson's disease woman." | 8.02 | Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy. ( Andriuta, D; Aubignat, M; Krystkowiak, P; Tir, M, 2021) |
| "Headache was the presenting and most prominent complaint, with daily episodes of short-lasting, intermittent, and paroxysmal attacks." | 5.31 | Recurrent short-lasting headache associated with paroxysmal hypertension: a clonidine-responsive syndrome. ( Dodick, DW, 2000) |
| "The efficacy of tizanidine in chronic tension-type headache was compared with placebo in a randomized, double-blind and cross-over study in 37 women aged 20 to 59 years with a history of headache for 7 months to 30 years (median 5 years)." | 5.07 | Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. ( Fogelholm, R; Murros, K, 1992) |
| "Seventy-eight patients with tension-type headache (TH) were treated with tizanidine hydrochloride (tizanidine)." | 5.07 | Treatment of tension-type headache with tizanidine hydrochloride: its efficacy and relationship to the plasma MHPG concentration. ( Awaki, E; Kowa, H; Shimomura, T; Takahashi, K, 1991) |
| "We compared the effects of transdermal clonidine and oral atenolol on acute exercise performance and on conditioning response to an 8-week program of regular aerobic exercise in young, otherwise healthy subjects with mild hypertension." | 5.06 | Comparative effects of transdermal clonidine and oral atenolol on acute exercise performance and response to aerobic conditioning in subjects with hypertension. ( Davidman, M; Davies, SF; Graif, JL; Husebye, DG; Iber, C; Maddy, MM; McArthur, CD; O'Connell, MB; Path, MJ, 1989) |
| "The efficacies of an 2-agonist clonidine and an 2-antagonist mianserin were compared in two treatment groups, common migraine and tension headache sufferers." | 5.05 | Headache and noradrenergic involvement: the effects of alpha 2-stimulants and alpha 2-antagonists. ( Agnoli, A; Denaro, A; Manna, V; Martucci, N; Ruggieri, S, 1985) |
| " For hemicrania we used cinnarizine, cyproheptadine, clonidine, histamine, pizotifene and reserpine; for cluster headache, cinnarizine, cyproheptadine, clonidine, histamine and reserpine; for tension headache, cyproheptadine; for psychogenic headache, allylpropylmalonylurea." | 5.04 | [Therapeutic possibilities in idiopathic headaches. Analysis of 1000 cases (author's transl)]. ( Agostoni, A; Brandi, G; Cottino, A; Gai, V; Gastaldi, L; Lisino, F; Nattero, G, 1975) |
| "We report a rare case of Shapiro's syndrome variantrevealed by episodes of headache with spontaneous hypothermia witheffectiveness of clonidine therapy in a 76-year-old Parkinson's disease woman." | 4.02 | Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy. ( Andriuta, D; Aubignat, M; Krystkowiak, P; Tir, M, 2021) |
| " In order to elucidate the relationship between noradrenergic and opioidergic functions, the plasma beta-endorphin (beta-EP) response to clonidine and the cortisol response to dexamethasone were evaluated together in 25 patients suffering from migraine without aura, and with chronic tension headache (MTH)." | 3.67 | Neuroendocrine evidence of deranged noradrenergic activity in chronic migraine. ( Facchinetti, F; Genazzani, AR; Martignoni, E; Nappi, G; Rossi, F; Sances, G, 1989) |
| "Apraclonidine seems to be a good alternative to cocaine to confirm Horner's syndrome." | 2.47 | [Acquired Horner's syndrome]. ( Alstadhaug, KB, 2011) |
| "Paroxysmal localized hyperhidrosis is a rare central autonomic nervous system disorder that can occur in combination with severe headache." | 1.62 | Paroxysmal localized Hyperhidrosis, a case-report: When excessive sweating occurs in combination with severe headaches. ( Schoofs, MW; van Coevorden, MH; Venhovens, J, 2021) |
| "Headache was the presenting and most prominent complaint, with daily episodes of short-lasting, intermittent, and paroxysmal attacks." | 1.31 | Recurrent short-lasting headache associated with paroxysmal hypertension: a clonidine-responsive syndrome. ( Dodick, DW, 2000) |
| " Oral administration was switched to the intracerebroventricular (ICV) route but pain relief was only transient despite a daily dosage up to 1." | 1.29 | [Cephalic cancer pain controlled by intraventricular administration of morphine and clonidine]. ( Bonnet, F; Loriferne, JF; N'Guyen, JP; Rostaing, S; Souchal Delacour, I, 1995) |
| " Clonidine in the stated dosage had no significant effect on blood pressure and heart rate." | 1.26 | [Treatment of menopausal symptoms with low doses of clonidine (author's transl)]. ( Lauritzen, C, 1982) |
| " The therapeutic cycles were standardized, for each drug, in the way of administration, dosage and total duration of the treatment." | 1.26 | [Therapeutic possibilities in idiopathic headaches. Analysis of about 1000 cases]. ( Agostoni, A; Brandi, G; Cottino, A; Gai, V; Gastaldi, L; Lisino, F; Nattero, G, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (58.33) | 18.7374 |
| 1990's | 6 (16.67) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 3 (8.33) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Aubignat, M | 1 |
| Tir, M | 1 |
| Krystkowiak, P | 1 |
| Andriuta, D | 1 |
| van Coevorden, MH | 1 |
| Schoofs, MW | 1 |
| Venhovens, J | 1 |
| Suter, MR | 1 |
| Sprenger, T | 1 |
| Taub, E | 1 |
| Besson, M | 1 |
| Nguyen, M | 1 |
| Tharani, S | 1 |
| Rahmani, M | 1 |
| Shapiro, M | 1 |
| Alstadhaug, KB | 1 |
| Bettucci, D | 1 |
| Testa, L | 1 |
| Calzoni, S | 1 |
| Mantegazza, P | 1 |
| Viana, M | 1 |
| Monaco, F | 1 |
| Prasad, S | 1 |
| Harpin, V | 1 |
| Poole, L | 1 |
| Zeitlin, H | 1 |
| Jamdar, S | 1 |
| Puvanendran, K | 1 |
| Sills, M | 1 |
| Congdon, P | 1 |
| Forsythe, I | 1 |
| Lauritzen, C | 1 |
| Diamond, S | 1 |
| Medina, JL | 1 |
| Loriferne, JF | 1 |
| Souchal Delacour, I | 1 |
| Rostaing, S | 1 |
| N'Guyen, JP | 1 |
| Bonnet, F | 1 |
| Feikema, WJ | 1 |
| Atanassoff, PG | 1 |
| Castro Bande, M | 1 |
| Dodick, DW | 1 |
| Fanchamps, A | 1 |
| Sillanpää, M | 1 |
| Barolin, GS | 1 |
| Nattero, G | 2 |
| Agostoni, A | 2 |
| Brandi, G | 2 |
| Cottino, A | 2 |
| Gai, V | 2 |
| Gastaldi, L | 2 |
| Lisino, F | 2 |
| Fogelholm, R | 1 |
| Murros, K | 1 |
| Shimomura, T | 1 |
| Awaki, E | 1 |
| Kowa, H | 1 |
| Takahashi, K | 1 |
| Bravo, EL | 1 |
| Dalessio, DJ | 1 |
| Davies, SF | 1 |
| Graif, JL | 1 |
| Husebye, DG | 1 |
| Maddy, MM | 1 |
| McArthur, CD | 1 |
| Path, MJ | 1 |
| O'Connell, MB | 1 |
| Iber, C | 1 |
| Davidman, M | 1 |
| Martignoni, E | 2 |
| Facchinetti, F | 2 |
| Rossi, F | 1 |
| Sances, G | 2 |
| Genazzani, AR | 2 |
| Nappi, G | 2 |
| Petraglia, F | 1 |
| Manzoni, GC | 1 |
| Sandrini, G | 1 |
| Martucci, N | 2 |
| Manna, V | 2 |
| Porto, C | 1 |
| Agnoli, A | 2 |
| Denaro, A | 1 |
| Ruggieri, S | 1 |
| Regli, F | 1 |
| Hansson, L | 1 |
| Hunyor, SN | 1 |
| Amery, AK | 1 |
| Bossaert, H | 1 |
| Fagard, RH | 1 |
| Verstraete, M | 1 |
| Clayden, JR | 1 |
| Bell, JW | 1 |
| Pollard, P | 1 |
| Picchione, N | 1 |
| Lageder, H | 1 |
| Hartl, O | 1 |
| Irsigler, K | 1 |
| Patten, JP | 1 |
| Hanington, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma[NCT01967576] | Phase 2 | 14 participants (Actual) | Interventional | 2013-10-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01967576)
Timeframe: Date treatment consent signed to date off study, approximately 54 months and 29 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Arm 1-Axitinib | 14 |
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever comes first. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01967576)
Timeframe: time from start of treatment to time of progression or death, up to 5 years and 9 months
| Intervention | months (Median) |
|---|---|
| 1/Arm 1-Axitinib | 7.7 |
Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or no-target) must have reduction in short axis to <10 mm. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT01967576)
Timeframe: Patients were assessed every 12 weeks (+/- week) up to 40.6 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Confirmed Partial Response | Complete Response | Stable Disease | Progressive Disease | |
| 1/Arm 1-Axitinib | 5 | 0 | 5 | 2 |
7 reviews available for clonidine and Bilateral Headache
| Article | Year |
|---|---|
[New concepts in the pathophysiology, diagnosis and treatment of neuropathic pain].
Topics: Analgesics; Capsaicin; Clonidine; Diabetic Neuropathies; Headache; Humans; Neuralgia; Pain Measureme | 2013 |
A review of the use of clonidine as a sleep aid in the child and adolescent population.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Chi | 2014 |
[Acquired Horner's syndrome].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Clonidine; Cocaine; Diagnosis, Differential; Fema | 2011 |
[Headache and chronic sleep deprivation: an often missed relationship in children and also in adults].
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Caffeine; Central Nervous System Stimulants; Child; Ch | 1999 |
[Subarachnoid anesthesia: 100 years of an established technique].
Topics: Adrenergic alpha-Agonists; Adult; Ambulatory Surgical Procedures; Analgesics; Anesthesia, Epidural; | 2000 |
[Classification, pathogenesis and drug therapy of migraine and related forms of headache].
Topics: Adrenergic beta-Antagonists; Animals; Caffeine; Clonidine; Dihydroergotamine; Drug Synergism; Epinep | 1975 |
Migraine.
Topics: Blood Vessels; Cacao; Cheese; Clonidine; Diet Therapy; Eye Diseases; Food; Headache; Hematologic Dis | 1971 |
15 trials available for clonidine and Bilateral Headache
| Article | Year |
|---|---|
Combination of tizanidine and amitriptyline in the prophylaxis of chronic tension-type headache: evaluation of efficacy and impact on quality of life.
Topics: Adult; Amitriptyline; Analgesics; Chronic Disease; Clonidine; Drug Therapy, Combination; Female; Hea | 2006 |
A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2007 |
Clonidine and childhood migraine: a pilot and double-blind study.
Topics: Child; Child, Preschool; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug Eruptions; F | 1982 |
Clonidine prophylaxis of childhood migraine and other vascular headache. A double blind study of 57 children;.
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Clonidine; Female; Headache; Humans; | 1977 |
[Therapeutic possibilities in idiopathic headaches. Analysis of 1000 cases (author's transl)].
Topics: Aspirin; Caffeine; Cinnarizine; Clinical Trials as Topic; Clonidine; Cyproheptadine; Drug Therapy, C | 1975 |
Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study.
Topics: Adult; Analgesics; Chronic Disease; Clonidine; Depression; Dose-Response Relationship, Drug; Double- | 1992 |
Treatment of tension-type headache with tizanidine hydrochloride: its efficacy and relationship to the plasma MHPG concentration.
Topics: Clonidine; Fatty Acids, Nonesterified; Female; Headache; Humans; Male; Methoxyhydroxyphenylglycol; M | 1991 |
Comparative effects of transdermal clonidine and oral atenolol on acute exercise performance and response to aerobic conditioning in subjects with hypertension.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Atenolol; Clonidine; Dermatitis, Contact; Do | 1989 |
Migraine and the noradrenergic control of vasomotricity: a study with alpha-2 stimulant and alpha-2 blocker drugs.
Topics: Adult; Clinical Trials as Topic; Clonidine; Dibenzazepines; Double-Blind Method; Female; Headache; H | 1985 |
Headache and noradrenergic involvement: the effects of alpha 2-stimulants and alpha 2-antagonists.
Topics: Adult; Clinical Trials as Topic; Clonidine; Dibenzazepines; Double-Blind Method; Female; Headache; H | 1985 |
[Treatment of vascular headaches].
Topics: Adrenergic beta-Antagonists; Carbamazepine; Cerebrovascular Disorders; Clonidine; Ergotamine; Female | 1973 |
Clonidine versus methyldopa. A double blind cross-over study comparing side effects of clonidine and methyldopa administered together with chlorthalidone at a dosage producing the same blood pressure lowering effect.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Clonidine; Consti | 1972 |
Menopausal flushing: double-blind trial of a non-hormonal medication.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Clonidine; Female; Gastrointestinal Diseases; Heada | 1974 |
[Long-term ambulatory treatment of arterial hypertension with clonidine].
Topics: Adult; Aged; Ambulatory Care; Clinical Trials as Topic; Clonidine; Drug Evaluation; Erectile Dysfunc | 1974 |
[Namestin (Clonidine), 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride in the treatment of essential hypertension (author's transl)].
Topics: Blood Pressure; Chlorides; Clinical Trials as Topic; Clonidine; Creatinine; Drug Evaluation; Fatigue | 1974 |
14 other studies available for clonidine and Bilateral Headache
| Article | Year |
|---|---|
Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy.
Topics: Aged; Agenesis of Corpus Callosum; Clonidine; Female; Headache; Humans; Hyperhidrosis; Hypothermia; | 2021 |
Paroxysmal localized Hyperhidrosis, a case-report: When excessive sweating occurs in combination with severe headaches.
Topics: Aged; Analgesics; Clonidine; Female; Headache; Humans; Hyperhidrosis; Hypothalamus; Sweating; Treatm | 2021 |
[Treatment of menopausal symptoms with low doses of clonidine (author's transl)].
Topics: Blood Pressure; Climacteric; Clonidine; Depression; Female; Genital Diseases, Female; Headache; Hear | 1982 |
Newer drug therapies for headache.
Topics: Antidepressive Agents; Aspirin; Bromocriptine; Clonidine; Cluster Headache; Dipyridamole; Headache; | 1980 |
[Cephalic cancer pain controlled by intraventricular administration of morphine and clonidine].
Topics: Analgesics, Opioid; Brain; Catheters, Indwelling; Cerebral Ventricles; Clonidine; Drug Therapy, Comb | 1995 |
Recurrent short-lasting headache associated with paroxysmal hypertension: a clonidine-responsive syndrome.
Topics: Acute Disease; Aged; Antihypertensive Agents; Clonidine; Headache; Humans; Hypertension; Male; Middl | 2000 |
[Drug therapy for headache: (author's transl)].
Topics: Analgesics; Anti-Inflammatory Agents; Antidepressive Agents; Clonidine; Dihydroergotamine; Ergotamin | 1977 |
[Therapeutic possibilities in idiopathic headaches. Analysis of about 1000 cases].
Topics: Cinnarizine; Clonidine; Cyproheptadine; Headache; Histamine; Humans; Methysergide; Migraine Disorder | 1976 |
Pheochromocytoma: new concepts and future trends.
Topics: Acidosis, Lactic; Adrenal Gland Neoplasms; Adult; Animals; Antihypertensive Agents; Antineoplastic C | 1991 |
Clonidine in chronic headaches.
Topics: Chronic Disease; Clonidine; Headache; Humans | 1991 |
Neuroendocrine evidence of deranged noradrenergic activity in chronic migraine.
Topics: Adult; beta-Endorphin; Clonidine; Dexamethasone; Female; Headache; Humans; Hydrocortisone; Male; Mid | 1989 |
Endorphin patterns within the headache spectrum disorders.
Topics: Adrenocorticotropic Hormone; Adult; beta-Endorphin; Chronic Disease; Clonidine; Cluster Headache; De | 1985 |
Blood pressure over-shoot due to acute clonidine (Catapres) withdrawal: studies on arterial and urinary catecholamines and suggestions for management of the crisis.
Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Catecholamines; Clonidine; Headache; Huma | 1973 |
Atypical migraine.
Topics: Aneurysm; Anxiety; Blood Pressure; Clonidine; Diagnosis, Differential; Ergotamine; Headache; Humans; | 1973 |